Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.

Autor: Riudavets M; Medical Oncology Department, Gustave Roussy cancer campus, Villejuif, France., Auclin E; Medical Oncology Department, Hôpital Européen Georges Pompidou, AP-HP Centre, Université Paris Cité, Paris, France., Mosteiro M; Medical Oncology Department, Institut Català d'Oncologia - ICO Hospitalet, Barcelona, Spain., Dempsey N; Medical Oncology Department, Jackson Memorial Hospital, Miami, FL., Majem M; Medical Oncology Department, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain., Prelaj A; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milan, Milano, Italy., López-Castro R; Medical Oncology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Bosch-Barrera J; Medical Oncology Department, Catalan Institute of Oncology, Hospital Universitari Josep Trueta, Girona, Spain., Pilotto S; Medical Oncology Department, University and Hospital Trust of Verona, Verona, Italy., Escalera E; Medical Oncology Department, Hospital Clínico de Salamanca, Salamanca, Spain., Tagliamento M; Medical Oncology Department, Gustave Roussy cancer campus, Villejuif, France; Internal Medicine and Medical Specialties Department, University of Genova, Genova, Italy., Mosquera J; Medical Oncology Department, Hospital Universitario A Coruña, A Coruña, Spain., Zalcman G; Université Paris Cité, Thoracic Oncology Department, CIC Inserm 1425, Hôpital Bichat-Claude Bernard, Paris, France., Aboubakar Nana F; Division of Pneumology, Cliniques universitaires Saint-Luc, Bruxelles, Belgium., Ponce S; Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain., Albarrán-Artahona V; Medical Oncology Department, Department of Medicine, Hospital Clinic, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, University of Barcelona, Barcelona, Spain., Dal Maso A; Medical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy., Spotti M; Medical Oncology Department, Hospital Alemán, Buenos Aires, Argentina., Mielgo X; Medical Oncology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain., Mussat E; Medical Oncology Department, Hôpital Européen Georges Pompidou, AP-HP Centre, Université Paris Cité, Paris, France., Reyes R; Medical Oncology Department, Department of Medicine, Hospital Clinic, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, University of Barcelona, Barcelona, Spain., Benítez JC; Medical Oncology Department, Gustave Roussy cancer campus, Villejuif, France; Medical Oncology Department, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain., Lupinacci L; Medical Oncology Department, Hospital Italiano, Buenos Aires, Argentina., Duchemann B; Medical Oncology Department, Hôpital Avicenne, Bobigny, France., De Giglio A; Medical Oncology Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy., Blaquier JB; Medical Oncology Department, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina., Audigier-Valette C; Medical Oncology Department, Centre Hospitalier Toulon Sainte-Mousse, Toulon, France., Scheffler M; Internal Medicine I Department, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany., Nadal E; Medical Oncology Department, Institut Català d'Oncologia - ICO Hospitalet, Barcelona, Spain., Lopes G; Medical Oncology Department, Jackson Memorial Hospital, Miami, FL., Signorelli D; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milan, Milano, Italy; Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy., Garcia-Campelo R; Medical Oncology Department, Hospital Universitario A Coruña, A Coruña, Spain., Menis J; Medical Oncology Department, Istituto Oncologico Veneto IRCCS, Padova, Italy., Bluthgen V; Medical Oncology Department, Hospital Alemán, Buenos Aires, Argentina., Campayo M; Medical Oncology Department, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain., Recondo G; Medical Oncology Department, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina., Besse B; Medical Oncology Department, Gustave Roussy cancer campus, Villejuif, France., Mezquita L; Medical Oncology Department, Department of Medicine, Hospital Clinic, Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, University of Barcelona, Barcelona, Spain. Electronic address: lmezquita@clinic.cat., Planchard D; Medical Oncology Department, Gustave Roussy cancer campus, Villejuif, France.

Publikováno v: Clinical lung cancer [Clin Lung Cancer] 2024 May; Vol. 25 (3), pp. 233-243.e8. Date of Electronic Publication: 2023 Nov 22.

25P Association between the lung immune prognostic index (LIPI) and durvalumab consolidation outcomes in patients with locally advanced non-small cell lung cancer (NSCLC)

Autor: Riudavets Melia, M., Auclin, E., Aboubakar Nana, Frank, Ponce Aix, S., Dal Maso, A., Bluthgen, V., Mielgo, X., Mussat, E., Reyes, R., Benítez, J., Lupinacci, L., Duchemann, B., de Giglio, A., Bautista, J., Audigier-Valette, C., Scheffler, M., Campayo, M., Besse, B., Planchard, D., Mezquita, L.

Publikováno v: Annals of Oncology, Vol. 32, no.Suppl 7, p. S1384 (2021)

BACKGROUND : The LIPI, based on pretreatment derived neutrophils/[leukocytes-neutrophils] ratio (dNLR) >3 and lactate dehydrogenase (LDH) >upper limit of normal (ULN), is associated with immune checkpoint inhibitors (ICI) outcomes in advanced non-sma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4f1cc5e289011afe7490ce83bf2da68
https://doi.org/10.1016/j.annonc.2021.10.041

MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC

Autor: Riudavets, M., Mezquita, L., Auclin, E., Benitez, J.C., Le Pechoux, C., Majem, M., Dempsey, N., Lobefaro, R., Nadal, E., Amores, A., Menis, J., Tagliamento, M., López-Castro, R., Ponce, S., Bosch-Barrera, J., Aboubakar, F., Mosquera, J., Pilotto, S., Reyes, R., Mielgo, X., Duchemann, B., Mosteiro, M., Mussat, E., De Giglio, A., Scheffler, M., Campayo, M., Botticella, A., Naltet, C., Lavaud, P., Lopes, G., Signorelli, D., Garcia-Campelo, R., Besse, B., Planchard, D.

Publikováno v: In Journal of Thoracic Oncology March 2021 16(3) Supplement:S161-S161

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

Autor: Sroussi M; Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France. Electronic address: marinesroussi@yahoo.com., Elaidi R; Association pour la Recherche et les Thérapeutiques Innovantes en Cancérologie, Paris, France., Fléchon A; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Lorcet M; Department of Medical Oncology, Centre Léon Bérard, Lyon, France., Borchiellini D; Department of Medical Oncology, Centre Antoine Lacassagne, Cote d'Azur University, Nice, France., Tardy MP; Department of Medical Oncology, Centre Antoine Lacassagne, Cote d'Azur University, Nice, France., Gravis G; Department of Medical Oncology, Institut Paoli-Calmettes Aix-Marseille University, Inserm, Centre National de la Recherche Scientifique, Centre de Recherche en Cancérologie de Marseille, Marseille, France., Guérin M; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Laguerre B; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France., Estrade F; Department of Medical Oncology, Centre Eugène Marquis, Rennes, France., Delva R; Department of Medical Oncology, Centre Paul Papin, Angers, France., Barthélémy P; Department of Medical Oncology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France., Loriot Y; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France., Lavaud P; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif, France., Lebret T; Department of Urology, Hôpital Foch, University of Paris Saclay, Suresnes, France., Neuzillet Y; Department of Urology, Hôpital Foch, University of Paris Saclay, Suresnes, France., Penel N; Department of Medical Oncology, Centre Oscar Lambret, Lille University, Lille, France., Houede N; Department of Medical Oncology, de Centre Hospitalier Universitaire Nimes, Montpellier University, Nimes, France., Pouessel D; Department of Medical Oncology, Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse, Toulouse, France., Rousseau B; Department of Medical Oncology, Hôpital Henri Mondor, Paris, France., Mussat E; Department of Medical Oncology, Hôpital Henri Mondor, Paris, France., Gross-Goupil M; Department of Medical Oncology, Centre Hospitalier Universitaire, Bordeaux, Aquitaine, France., Culine S; Department of Medical Oncology, Hôpital St Louis, University of Paris Diderot, Paris, France., Gauthier H; Department of Medical Oncology, Hôpital St Louis, University of Paris Diderot, Paris, France., Gobert A; Department of Medical Oncology, Hôpital Pitié-Salpêtrière, Paris, France., Roupret M; GRC no5, Oncotype-URO, Assistance Publique - Hôpitaux de Paris, Sorbonne University, and Department of Urology, Hôpital Pitié-Salpêtrière, Paris, France., Huillard O; Department of Medical Oncology, Hôpital Cochin, Paris, France., Tartas S; Department of Medical Oncology, Centre Hospitalier Universitaire Lyon, Lyon, France., Radulescu C; Department of Pathology, Hôpital Foch, Suresnes, France., Allory Y; Department of Pathology, Hôpital Foch, Suresnes, France; Department of Pathology, Institut Curie, Saint-Cloud, France., Oudard S; Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France; Association pour la Recherche et les Thérapeutiques Innovantes en Cancérologie, Paris, France; University René Descartes, Paris, France.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2020 Aug; Vol. 18 (4), pp. 295-303.e3. Date of Electronic Publication: 2019 Dec 05.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.